Trump’s CMS Inherits Medicare Price ‘Facilitator’ System Build Out; Should Pharma Be Worried?

The potential for manufacturer liability may become a concern if problems providing rebates to pharmacies on negotiated drugs emerge because the system goes awry, a former CMS official suggested in an interview with the Pink Sheet.